NUVL
Nuvalent, Inc.Healthcare · $9.1B market cap
Verdict
We can't put a fair value on NUVL right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow NUVL
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
None of the investors we track holds NUVL right now. In Q2 2026, 1 sold out. Who we track
Moves in Q2 2026
Sold out: Polen Capital Management
About Nuvalent, Inc.
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Jul 15, 2026. How the Payback Price works